Ballard, Elizabeth D. http://orcid.org/0000-0001-5304-0127
Zarate, Carlos A. Jr.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857, ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 29 May 2020
Accepted: 17 November 2020
First Online: 22 December 2020
Competing interests
: C.A.Z. is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. E.D.B. has no competing interests.